Last €8.14 EUR
Change Today -0.074 / -0.90%
Volume 0.0
3O8 On Other Exchanges
As of 1:50 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of products targeting inflammation, coagulopathies and disorders of the central nervous system. The company’s most clinically advanced products are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. The company’s PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical uses both during and after surgery. The company has five clinical-stage development programs. In addition, the company has a deep and diverse pipeline of preclinical programs, as well as a platform capable of unlocking new drug targets. For each of its products and programs, the company has retained all manufacturing, marketing and distribution rights. Clinical Programs PharmacoSurgery Platform The company generates from its PharmacoSurgery platform proprietary product candidates that are combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. Supplied in pre-dosed, pre-formulated, single-use containers, its PharmacoSurgery product candidates are added to standard surgical irrigation solutions and delivered intra-operatively to the site of tissue trauma throughout the surgical procedure. This results in the delivery of low concentrations of agents with minimal systemic uptake and reduced risk of adverse side effects, and does not require a surgeon to change his or her operating procedure. The company’s PharmacoSurgery product candidates specifically include active pharmaceutical ingredients (APIs), contained in generic drugs approved by the U.S. Food and Drug Administration (FDA) with established profiles of safety and pharmacologic activities, and are eligible for submission under the potentially less-costly and time-consuming Section 505(b)(2) New Drug Application (NDA) process. OMS302—Ophthalmology OMS302 is its product candidate being developed for use during intraocular lens replacement (ILR) surgery, including cataract and other lens replacement surgery. OMS302 is a proprietary combination of ketorolac, an anti-inflammatory API, and phenylephrine, a mydriatic API. OMS302 is added to standard irrigation solution used in ILR surgery and delivered intracamerally to maintain intraoperative mydriasis (pupil dilation), to prevent surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. OMS302 has been evaluated in Phase 1/Phase 2, Phase 2b and Phase 3 clinical trials in patients undergoing cataract extraction and lens replacement procedures and refractive lens exchange. OMS103HP—Arthroscopy OMS103HP is the company’s PharmacoSurgery product being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and was designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. OMS103HP is a proprietary combination of anti-inflammatory/analgesic APIs, each with safety and pharmacologic profiles. Each of the APIs are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter, or OTC, or prescription drug products and has established and well-characterized safety profiles. OMS201—Urology OMS201 is the company’s PharmacoSurgery product being developed for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. OMS201 is a proprietary combination of an anti-inflammatory API and a smooth muscle relaxant API, and is intended for local delivery to the bladder, ureter, urethra, and other urinary tract structures during urological procedures. Both of the AP

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3O8:GR €8.14 EUR -0.074

3O8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3O8.
View Industry Companies

Industry Analysis


Industry Average

Valuation 3O8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 213.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 216.9x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at